BDZ, thanks for the reply. I have to run and will review posts in more detail later. My initial take is that the sub studies are more for further drug development but may not do much in terms of real bankability at this early stage. The primary endpoint is therefore the main consideration, which isn’t a great revelation on my part. Thanks again as always.